AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Find an Eye MD near you!
- Details
The U.S. FDA has granted orphan drug designation to AGTC’s gene therapy product candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene.
- Details
A randomized trial from DRCR.net has shown ranibizumab is as effective as panretinal photocoagulation in treating PDR, and better than laser in preserving patients’ peripheral and night vision.
- Details
Long-term response to anti-VEGF therapy in DME may be predicted after 3 injections at 12 weeks
Read more: Long-term response to anti-VEGF therapy for DME can be predicted by 12 Weeks
- Details
Pfizer today announced it reached a $160 billion deal to merge with Allergan.
- Details
Eyegate Pharmaceuticals announced promising interim data showing iontophoresis can non-invasively deliver dexamethasone phosphate to the posterior segment.
- Details
The authors of this randomized trialfound that neither cataract surgery nor IOL type have a significant impact on circadian photoentrainment or sleep quality.